Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3%
Nautilus Biotechnology established a new at-the-market (ATM) Sales Agreement with TD Cowen to sell up to $125 million of common stock, while simultaneously terminating its February 28, 2024 ATM agreement with the same counterparty. The new program allows Nautilus to direct timing, size, and pricing…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.